Collegium Pharmaceutical (NASDAQ:COLL) Sets New 1-Year Low – Here’s Why

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) reached a new 52-week low on Tuesday . The stock traded as low as $28.30 and last traded at $28.30, with a volume of 534 shares trading hands. The stock had previously closed at $28.62.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on COLL. Piper Sandler reaffirmed a “neutral” rating and set a $37.00 price objective on shares of Collegium Pharmaceutical in a report on Friday, October 11th. StockNews.com cut shares of Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, October 23rd. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $42.60.

Collegium Pharmaceutical Stock Up 14.4 %

The company has a market cap of $1.08 billion, a PE ratio of 14.37 and a beta of 0.82. The firm has a 50-day simple moving average of $30.61 and a two-hundred day simple moving average of $34.05. The company has a debt-to-equity ratio of 3.43, a current ratio of 0.97 and a quick ratio of 0.88.

Institutional Investors Weigh In On Collegium Pharmaceutical

Several hedge funds have recently modified their holdings of the company. JPMorgan Chase & Co. increased its stake in Collegium Pharmaceutical by 173.6% in the third quarter. JPMorgan Chase & Co. now owns 277,204 shares of the specialty pharmaceutical company’s stock valued at $10,711,000 after purchasing an additional 175,892 shares during the last quarter. Principal Financial Group Inc. lifted its holdings in shares of Collegium Pharmaceutical by 3.9% during the 3rd quarter. Principal Financial Group Inc. now owns 1,745,818 shares of the specialty pharmaceutical company’s stock worth $67,459,000 after acquiring an additional 64,958 shares during the period. Franklin Resources Inc. boosted its position in shares of Collegium Pharmaceutical by 13.4% in the third quarter. Franklin Resources Inc. now owns 30,625 shares of the specialty pharmaceutical company’s stock worth $1,164,000 after acquiring an additional 3,620 shares during the last quarter. Sanctuary Advisors LLC boosted its position in shares of Collegium Pharmaceutical by 10.7% in the third quarter. Sanctuary Advisors LLC now owns 17,976 shares of the specialty pharmaceutical company’s stock worth $695,000 after acquiring an additional 1,731 shares during the last quarter. Finally, TD Private Client Wealth LLC grew its holdings in Collegium Pharmaceutical by 39.5% in the third quarter. TD Private Client Wealth LLC now owns 1,707 shares of the specialty pharmaceutical company’s stock valued at $66,000 after purchasing an additional 483 shares during the period.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.